New drug combo aims to boost lymphoma treatment
NCT ID NCT07588698
First seen May 17, 2026 · Last updated Jun 17, 2026 · Updated 5 times
Summary
This study tests a new drug, epcoritamab, added to standard chemotherapy (R-CHOP) for people newly diagnosed with aggressive B-cell lymphoma. The main goal is to check safety, especially a side effect called cytokine release syndrome. About 20 adults will join this early-phase trial to see if the combination is safe enough for larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, NON-HODGKIN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zuckerberg San Francisco General
San Francisco, California, 94110, United States
Contact Phone: •••-•••-••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.